Patents Assigned to BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
  • Patent number: 11932602
    Abstract: The present disclosure provides a method for preparing a nicotinamide mononucleotide cocrystal, and aims to solve the technical problems of larger content/weight difference and inconsistent quality of nicotinamide mononucleotide (NMN) medicines or health care products due to poor fluidity of existing nicotinamide mononucleotide crystals. The method includes the steps of mixing nicotinamide mononucleotide as an active pharmaceutical ingredient with isonicotine as a cocrystal former by adopting solution synthesis and then performing crystal precipitation. The method has the advantages of simple operation and wide application range.
    Type: Grant
    Filed: June 6, 2022
    Date of Patent: March 19, 2024
    Assignees: BONTAC BIO-ENGINEERING(SHENZHEN) CO., LTD, ZHONGSHAN BONTAC BIO-TECHNOLOGY CO., LTD
    Inventors: Zhang Zhang, Ming Chen
  • Patent number: 11312948
    Abstract: The present invention provides a method for preparation of an enzyme-modified stevia sugar. The method includes the steps of adding a ?-fructosidase to a solution in which a stevia sugar raw material and sucrose are dissolved to obtain a reaction solution, adjusting the pH of the reaction solution to be 5.0-8.0, maintaining a reaction temperature at 20-45° C., and after a reaction with stirring, collecting the enzyme-modified stevia sugar. The stevia sugar raw material includes one or more of stevioside and rebaudioside A, and the ?-fructosidase is derived from Microbacterium saccharophilum or Aspergillus japonicus. The preparation method takes a short time, is efficient and convenient to operate, low in cost, high in conversion rate, green and environmentally friendly, and can be widely applied to industrial scale production. The present invention further provides an enzyme for preparation of the enzyme-modified stevia sugar and application thereof.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: April 26, 2022
    Assignee: BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
    Inventors: Rongzhao Fu, Lihui Liu, Ming Jiang, Yufeng Liu, Wenshan Liu, Xiaochun Chen
  • Patent number: 11299721
    Abstract: An acid phosphatase mutant, and method for preparing nicotinamide riboside by same. The mutant is a protein of the following (a), (b) or (c): (a) a protein, having an amino acid sequence shown in SEQ ID NO: 3; (b) a protein, derived from (a), having catalytic activity higher than an acid phosphatase parent having an amino acid sequence shown in SEQ ID NO: 2, obtained by substituting, deleting or adding several amino acids in the amino acid sequence shown in SEQ ID NO: 3, using nicotinamide mononucleotide as a substrate; (c) a protein, having catalytic activity higher than the acid phosphatase shown in SEQ ID NO: 2, having 90% or more homology with the amino acid sequence of the protein defined by (a) or (b), and using nicotinamide mononucleotide as a substrate. It is used to prepare nicotinamide riboside and the conversion rate can be 99%.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: April 12, 2022
    Assignees: Bontac Bio-Engineering (Shenzhen) Co., Ltd, Bontac Invitrolife Bio-Technology (Shenzhen) Co., Ltd, Jiangxi Bonzymes Biotechnology Co., Ltd.
    Inventors: Rongzhao Fu, Zhenwei Li, Min Wang, Xinglin Guo
  • Patent number: 11052100
    Abstract: A nicotinamide riboside composition and preparation method thereof, the icotinamide riboside composition comprises nicotinamide riboside and/or a salt thereof and konjac glucomannan or rebaudioside A. The nicotinamide riboside composition provided by the present invention, used to increase the concentration of NAD in cells, thereby preventing and improving various unhealthy conditions caused by NAD deficiency. is stable in property and easy to store and transport.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: July 6, 2021
    Assignees: BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD, BONTAC INVITROLIFE BIO-TECHNOLOGY (SHENZHEN) CO., LTD, JIANGXI BONZYMES BIOTECHNOLOGY CO., LTD.
    Inventors: Rongzhao Fu, Zhenwei Li, Xinglin Guo
  • Patent number: 11040996
    Abstract: The present invention provides a method for preparing nicotinamide mononucleotide (NMN) by bioanalysis. The method includes a step of catalytically reacting a plurality of raw materials including nicotinamide, ATP, and ribose in the presence of nicotinamide phosphoribosyltransferase (Nampt), ribose phosphate pyrophosphokinase, and ribokinase, to prepare the NMN.
    Type: Grant
    Filed: July 30, 2016
    Date of Patent: June 22, 2021
    Assignee: BONTAC BIO-ENGINEERING(SHENZHEN) CO., LTD
    Inventors: Rongzhao Fu, Qi Zhang
  • Patent number: 10894059
    Abstract: An NADH compound, and a formulation and use thereof, relating to the technical field of biomedicine and health care products. The NADH compound includes NADH or its physiologically acceptable salt and L-carnitine or its physiologically acceptable salt, and can be used as a weight loss product. The NADH compound has an increased effect in weight loss, and may achieve long-term drug administration of the product.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: January 19, 2021
    Assignee: BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
    Inventors: Rongzhao Fu, Xieguo Yan, Zhu Dai
  • Patent number: 10765967
    Abstract: The present invention relates to a process for purifying crude NADPH product prepared by biocatalysis. The objective of the present invention is to solve the technical problems of low yield and low purity of the purified product in the existing ion exchange resin method. The present invention comprises sequentially the following steps: pretreatment, loading onto an ion column, elution of cations, pre-elution of impurities etc. The yield of the purification process disclosed in the present invention can be up to 85% or higher and the purified NADPH has a purity of up to 98% or higher.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: September 8, 2020
    Assignees: BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD, JIANGXI BONTAC GREEN-BIOCATALYSIS ECOINDUSTRIAL PARK CO., LTD.
    Inventors: Qi Zhang, Dongmin Zhang, Rongzhao Fu
  • Patent number: 10519429
    Abstract: The present invention discloses a Nicotinamide phosphoribosyltransferase (nampt) mutant and use thereof. The present invention relates to a nicotinamide phosphoribosyltransferase (Nampt) mutant artificially obtained through genic site-directed mutation. An object of the present invention is to provide a Nampt mutant having a catalytic activity higher than that of a conventional wild type parent, wherein the enzymatic activity of the Nampt mutant provided in the present invention is 1.2-6.9 times of the enzymatic activity of the parent.
    Type: Grant
    Filed: November 22, 2018
    Date of Patent: December 31, 2019
    Assignee: BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
    Inventors: Rongzhao Fu, Qi Zhang
  • Publication number: 20190336887
    Abstract: The present invention relates to a process for purifying crude NADPH product prepared by biocatalysis. The objective of the present invention is to solve the technical problems of low yield and low purity of the purified product in the existing ion exchange resin method. The present invention comprises sequentially the following steps: pretreatment, loading onto an ion column, elution of cations, pre-elution of impurities etc. The yield of the purification process disclosed in the present invention can be up to 85% or higher and the purified NADPH has a purity of up to 98% or higher.
    Type: Application
    Filed: December 14, 2016
    Publication date: November 7, 2019
    Applicants: BONTAC BIO-ENGINEERING(SHENZHEN) CO.,LTD, JIANGXI BONTAC GREEN-BIOCATALYSIS ECOINDUSTRIAL PARK CO.,LTD
    Inventors: Qi ZHANG, Dongmin ZHANG, Rongzhao FU
  • Publication number: 20190153407
    Abstract: The present invention discloses a Nicotinamide phosphoribosyltransferase (nampt) mutant and use thereof. The present invention relates to a nicotinamide phosphoribosyltransferase (Nampt) mutant artificially obtained through genic site-directed mutation. An object of the present invention is to provide a Nampt mutant having a catalytic activity higher than that of a conventional wild type parent, wherein the enzymatic activity of the Nampt mutant provided in the present invention is 1.2-6.9 times of the enzymatic activity of the parent.
    Type: Application
    Filed: November 22, 2018
    Publication date: May 23, 2019
    Applicant: BONTAC BIO-ENGINEERING(SHENZHEN) CO.,LTD
    Inventors: Rongzhao FU, Qi ZHANG
  • Patent number: 10214552
    Abstract: A method for purifying ?-nicotinamide mononucleotide (NMN) includes: sequentially microfiltrating and nanofiltrating a crude product solution containing NMN using membrane concentration devices to obtain a concentrated crude product solution; adjusting the concentrated crude product solution to pH 3-7 to obtain a loading solution, loading the loading solution onto a preparative reverse phase high performance liquid chromatographic column, and purifying by gradient elution using an octadecylsilane-bonded silica gel as a stationary phase, a hydrochloric acid solution at pH 3-7 as a mobile phase A, and 100% ethanol as a mobile phase B, to obtain a purified sample solution; concentrating the purified sample solution by nanofiltration and freeze drying in a vacuum freeze drier to obtain a purified NMN.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: February 26, 2019
    Assignee: BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD.
    Inventors: Rongzhao Fu, Zhu Dai, Qi Zhang
  • Patent number: 10214556
    Abstract: A method for purifying a salt of reduced form of ?-nicotinamide adenine dinucleotide (NADH) includes: sequentially microfiltrating and nanofiltrating a reaction solution obtained after an enzymatic reaction, collecting a concentrate for use; adding an ion pair reagent to the concentrate, and purifying by gradient elution to obtain a purified filtrate using a reverse-phase chromatographic column as a stationary phase, a buffer solution as a phase A, and ethanol as a phase B; changing the cations in the purified filtrate into sodium ions to obtain a filtrate by using a cation exchange resin; and nanofiltrating the filtrate, and freeze drying in a vacuum freeze drier. The method results in an excellent purity and yield of a salt of NADH that meets requirements in industry.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: February 26, 2019
    Assignee: BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
    Inventors: Rongzhao Fu, Zhu Dai, Qi Zhang
  • Patent number: 10174298
    Abstract: The present invention discloses a Nicotinamide phosphoribosyltransferase (nampt) mutant and use thereof. The present invention relates to a nicotinamide phosphoribosyltransferase (Nampt) mutant artificially obtained through genic site-directed mutation. An object of the present invention is to provide a Nampt mutant having a catalytic activity higher than that of a conventional wild type parent, wherein the enzymatic activity of the Nampt mutant provided in the present invention is 1.2-6.9 times of the enzymatic activity of the parent.
    Type: Grant
    Filed: July 30, 2016
    Date of Patent: January 8, 2019
    Assignee: BONTAC BIO-ENGINEERING(SHENZHEN) CO., LTD
    Inventors: Rongzhao Fu, Qi Zhang
  • Publication number: 20180230443
    Abstract: The present invention discloses a Nicotinamide phosphoribosyltransferase (nampt) mutant and use thereof. The present invention relates to a nicotinamide phosphoribosyltransferase (Nampt) mutant artificially obtained through genic site-directed mutation. An object of the present invention is to provide a Nampt mutant having a catalytic activity higher than that of a conventional wild type parent, wherein the enzymatic activity of the Nampt mutant provided in the present invention is 1.2-6.9 times of the enzymatic activity of the parent.
    Type: Application
    Filed: July 30, 2016
    Publication date: August 16, 2018
    Applicant: BONTAC BIO-ENGINEERING(SHENZHEN) CO.,LTD
    Inventors: Rongzhao FU, Qi ZHANG
  • Publication number: 20180162895
    Abstract: The present invention provides a method for preparing nicotinamide mononucleotide (NMN) by biocatalysis. The method includes a step of catalytically reacting a plurality of raw materials including nicotinamide, ATP, and ribose in the presence of nicotinamide phosphoribosyltransferase (Nampt), ribose phosphate pyrophosphokinase, and ribokinase, to prepare the NMN.
    Type: Application
    Filed: July 30, 2016
    Publication date: June 14, 2018
    Applicant: BONTAC BIO-ENGINEERING(SHENZHEN) CO.,LTD
    Inventors: Rongzhao FU, Qi ZHANG
  • Publication number: 20170165282
    Abstract: A medication having nicotinamide mononucleotide as the active ingredient, and the use of nicotinamide mononucleotide in preparing medications for the prevention and treatment of arteriosclerosis and cardiovascular and cerebrovascular diseases caused by arteriosclerosis.
    Type: Application
    Filed: December 11, 2015
    Publication date: June 15, 2017
    Applicant: BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD.
    Inventors: Rongzhao FU, Yanyan CAI
  • Publication number: 20160340377
    Abstract: The present invention discloses a method for purifying oxidized form of ?-nicotinamide adenine dinucleotide, comprising the steps of: sequentially microfiltrating and nanofiltrating a reaction solution obtained after an enzymatic reaction by using filteration membranes, to collect a concentrate for use; then adding an acid to the concentrated filtrate, to adjust the pH of the concentrate, and purifying by gradient elution using a reverse-phase chromatographic column as a stationary phase, a buffer solution as a phase A, and ethanol as a phase B; and concentrating the purified solution by nanofiltrating it with a filtration membrance, and then freeze drying it in a vacuum freeze drier. In the present invention, the oxidized form of ?-nicotinamide adenine dinucleotide is purified by reverse phase high performance liquid chromatography, such that the oxidized form of ?-nicotinamide adenine dinucleotide has a high purity and high yield, thus meeting the requirements in industry.
    Type: Application
    Filed: December 4, 2015
    Publication date: November 24, 2016
    Applicant: BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
    Inventors: Rongzhao FU, Zhu DAI, Qi ZHANG